Praxis Precision Medicines, Inc.

The biopharmaceutical company specializes in developing precision therapies for central nervous system (CNS) disorders caused by imbalances in neuronal excitation and inhibition. Leveraging human genetic insights from epilepsies, the enterprise discovers and develops therapies using two proprietary platforms: Cerebrum, which focuses on small molecules, and Solidus, an antisense oligonucleotide engine. Its primary clinical-stage pipeline comprises small molecule candidates such as ulixacaltamide, vormatrigine, and relutrigine, as well as the oligonucleotide candidate elsunersen. The company creates these targeted therapeutics for individuals diagnosed with movement disorders, such as essential tremor, alongside severe genetic conditions like developmental and epileptic encephalopathies and common adult epilepsies.

The organization conducts clinical trials and development initiatives across diverse international territories by engaging a global network of contract research organizations and scientific collaborators. Additionally, the company maintains regional development and commercialization partnerships, including an agreement spanning China, Hong Kong, Macau, and Taiwan. The provided text does not disclose the location of the corporate headquarters.

Summary of the business section of Praxis Precision Medicines's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of February 16, 2026, we have 168 employees and plan to continue to grow as we advance the potential of our pipeline.”